What Happens After Stopping Ozempic or Wegovy?
A data-driven review of what the clinical evidence shows — including both the regain statistics and the substantial minority who maintained meaningful weight loss.
Updated: March 2026 · Source: Wilding et al. (2022) — Weight regain after semaglutide withdrawal. STEP 1 extension. Diabetes Obes Metab.
About this page: The data below comes from the STEP 1 extension study (Wilding et al., 2022, Diabetes & Obesity & Metabolism), which followed 327 participants for 68 weeks of semaglutide treatment followed by 52 weeks of observation after stopping. This is the most rigorous dataset on post-treatment outcomes. We present both the regain data and the maintenance data without framing designed to alarm or reassure.
What the STEP 1 Extension Found
During 68 weeks of semaglutide 2.4mg treatment, the 327 participants in the extension study lost a mean of 17.3% of body weight (SD 9.3%). After stopping, participants were followed for another 52 weeks.
Weight Trajectory (Mean, % of starting body weight)
Mean values. Individual variation was substantial (SD ±9.3% during treatment, ±8.9% at week 120).
The headline finding: participants regained approximately 67% of their prior weight loss within 52 weeks of stopping semaglutide. Placebo participants regained only 1.9 percentage points over the same period, confirming the regain was attributable to medication discontinuation.
Not Everyone Regains: The Other Half of the Story
The mean regain statistic, while significant, does not describe the full range of outcomes. The STEP 1 extension also found:
of participants still maintained clinically meaningful weight loss (≥5% of body weight) at week 120 — one year after stopping treatment.
This means that while the average participant regained most of their loss, nearly half maintained a clinically meaningful outcome one year after stopping. The wide standard deviations (±9.3% during treatment, ±8.9% at week 120) reflect substantial individual variation.
Predictors of maintaining weight loss after stopping are not fully characterized in published literature, but behavioral changes sustained during treatment (dietary habits, physical activity, relationship with food) likely play a role.
Why Weight Returns: Biological Mechanisms
Weight regain after stopping GLP-1 medications is not a matter of willpower. It reflects the underlying biology of obesity as a chronic, relapsing condition. Several mechanisms contribute:
Cardiometabolic Effects Also Revert
The STEP 1 extension study found that not just weight, but cardiometabolic risk markers also largely reverted toward baseline after stopping treatment. This included measures such as waist circumference, blood pressure, lipid profiles, and blood glucose markers that had improved during treatment.
This finding has implications for how GLP-1 medications are framed: they are effective while being taken, but their cardiometabolic benefits appear to require continued treatment for maintenance. This parallels how other chronic disease medications (such as blood pressure medications) require ongoing use for ongoing effect.
Tapering vs. Abrupt Stop
A 2024 study examined whether tapering (gradually reducing dose) versus abrupt discontinuation affected outcomes. The study found that tapering was associated with more stable body weight compared to abrupt discontinuation, though both groups ultimately showed the same tendency toward weight regain over the longer term.
Clinical note: The decision to taper or stop abruptly should be made with your prescribing physician based on your individual circumstances, insurance, access, and goals. There is currently no FDA-mandated tapering protocol for GLP-1 medications. Do not modify your prescribed regimen without consulting your provider.
Evidence-Informed Strategies for Maintaining Weight Loss
While no strategy fully counteracts the biological drive toward weight regain, research and clinical experience suggest the following approaches help maximize maintenance:
Preserve muscle mass during treatment
Higher muscle mass improves resting metabolic rate. The joint advisory recommends resistance training 3x/week + adequate protein (1.0–1.5 g/kg/day) throughout GLP-1 treatment.
Continue resistance training after stopping
Resistance training is the most evidence-backed intervention for minimizing regain. It counteracts metabolic adaptation and preserves lean mass.
Maintain protein intake
High protein diets (1.2–1.5 g/kg/day) support satiety, reduce the hunger rebound effect, and help preserve muscle during weight changes.
Behavioral and sustainable changes
Structured eating patterns, food environment modifications, and sustainable habits established during treatment are the most durable contributors to long-term maintenance.
Related Tools & Guides
Primary Source
Wilding et al. (2022) — Weight regain after semaglutide withdrawal. STEP 1 extension. Diabetes Obes Metab. PubMed PMID 35441470. n=327 participants. 68-week treatment phase + 52-week off-treatment observation.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.